A detailed history of Citigroup Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 12,162 shares of APLS stock, worth $403,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,162
Previous 42,669 71.5%
Holding current value
$403,048
Previous $1.64 Million 78.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$28.84 - $41.15 $879,821 - $1.26 Million
-30,507 Reduced 71.5%
12,162 $350,000
Q2 2024

Aug 12, 2024

SELL
$38.07 - $59.71 $8.34 Million - $13.1 Million
-219,039 Reduced 83.7%
42,669 $1.64 Million
Q1 2024

May 10, 2024

BUY
$55.39 - $72.47 $9.7 Million - $12.7 Million
175,167 Added 202.41%
261,708 $15.4 Million
Q4 2023

Feb 09, 2024

SELL
$37.14 - $64.82 $1.13 Million - $1.97 Million
-30,355 Reduced 25.97%
86,541 $5.18 Million
Q3 2023

Nov 09, 2023

BUY
$23.65 - $89.22 $872,945 - $3.29 Million
36,911 Added 46.15%
116,896 $4.45 Million
Q2 2023

Aug 10, 2023

SELL
$76.68 - $93.31 $3.33 Million - $4.05 Million
-43,422 Reduced 35.19%
79,985 $7.29 Million
Q1 2023

May 11, 2023

BUY
$46.59 - $66.96 $1.92 Million - $2.77 Million
41,307 Added 50.31%
123,407 $8.14 Million
Q4 2022

Feb 09, 2023

SELL
$43.24 - $61.04 $680,251 - $960,281
-15,732 Reduced 16.08%
82,100 $4.25 Million
Q3 2022

Nov 10, 2022

SELL
$44.76 - $69.66 $184,769 - $287,556
-4,128 Reduced 4.05%
97,832 $6.68 Million
Q2 2022

Aug 10, 2022

BUY
$35.07 - $59.21 $2.64 Million - $4.46 Million
75,276 Added 282.1%
101,960 $4.61 Million
Q1 2022

May 12, 2022

SELL
$35.46 - $54.12 $3.3 Million - $5.03 Million
-93,004 Reduced 77.71%
26,684 $1.36 Million
Q4 2021

Feb 10, 2022

BUY
$30.74 - $49.16 $1.52 Million - $2.43 Million
49,396 Added 70.27%
119,688 $5.66 Million
Q3 2021

Nov 10, 2021

BUY
$31.4 - $69.84 $2.21 Million - $4.91 Million
70,292 New
70,292 $2.32 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.